April 07, 2021
Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds
From: Multiple Sclerosis News Today
By: Marta Figueiredo, PhD
Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS) patients switching treatment, according to the latest Spherix Global Insights’ report…(read more).